Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Monalizumab (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 05 Apr 2017 Results (n=13) of the phase I part of the trial, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 02 Mar 2017 Results published in an Innate Pharma Media Release
    • 02 Mar 2017 According to an Innate Pharma media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top